Suprachoroidal Bevacizumab Versus Intravitreal Bevacizumab in Diabetic Macular Edema

Diabetic macular edema is an eye condition caused by diabetes in which fluid accumulates in the central part of the retina, leading to blurred vision and potentially permanent vision loss. Bevacizumab is a medicine that blocks vascular endothelial growth factor (VEGF), a protein involved in abnormal leakage from blood vessels. It is commonly used as an injection into the eye to treat this condition. This study aims to compare two methods of delivering bevacizumab in patients with center-involving diabetic macular edema. Participants will be randomly assigned to one of two groups. The first group will receive bevacizumab injections into the vitreous cavity of the eye (intravitreal injection), while the second group will receive injections into the space between the sclera and choroid of the eye (suprachoroidal injection). Both groups will receive injections once a month for three months. The study will compare changes in vision and central retinal thickness, measured using an eye examination and optical coherence tomography (OCT), from the start of the study to the four-month…

• Central Macular Thickness
• Visual Acuity

1. Study completion expected

   Dec 2027

2. Primary completion expected

   Oct 2027

3. Registered

   Oct 27, 2026

4. Started

   Oct 1, 2026